Chemotherapy-Induced Anemia
Chemotherapy-induced anemia (CIA) diagnosis, treatment, and management. Find information on anemia due to chemotherapy, including clinical documentation tips, ICD-10 codes, medical coding guidelines, and healthcare provider resources for supporting patients with CIA. Learn about hemoglobin levels, red blood cell counts, and anemia symptoms in chemotherapy patients.
Low red blood cell count caused by chemotherapy drugs.
Fatigue, weakness, shortness of breath, pale skin, dizziness, fast heart rate.
Oncology clinics, hospitals (inpatient and outpatient), cancer treatment centers.
ICD-10 Code Families
Complete code families applicable to D64.81
When to use each related code
| Description | When to use |
|---|---|
| Anemia caused by chemotherapy drugs. | Use for anemia directly related to chemotherapy treatment. Consider staging. |
| Anemia due to blood loss. | Use when anemia is caused by acute or chronic blood loss from any source. |
| Anemia caused by iron deficiency. | Use when anemia is due to insufficient iron for red blood cell production. Check ferritin levels. |
Best-practice checklist
- ✓Document specific chemotherapy agent(s) used.
- ✓Record hemoglobin/hematocrit levels pre- and post-chemotherapy.
- ✓Note any signs/symptoms of anemia (fatigue, pallor, dyspnea).
- ✓Specify if anemia is acute or chronic.
- ✓Assess and document impact on patient's quality of life.
Common pitfalls to avoid
Coding CIA without specifying the type (e.g., aplastic, hemolytic) can lead to rejected claims or lower reimbursement.
Lack of clear documentation linking anemia to chemotherapy may cause coding errors and compliance issues.
Incorrectly sequencing CIA as the principal diagnosis when another condition is more significant can impact DRG assignment.
Best-practice tips
- 01Monitor hemoglobin/hematocrit (ICD-10-CM D63.0) regularly.
- 02Consider erythropoiesis-stimulating agents (ESAs) per guidelines (NCCN/ASCO).
- 03Document anemia severity and impact on patient function (CDI best practice).
- 04Transfuse packed red blood cells (PRBCs) judiciously for symptomatic anemia.
- 05Educate patient on anemia management, including iron supplementation (ICD-10-CM D50.9).
Step-by-step checklist
- 1
Confirm recent chemotherapy treatment documented
- 2
Hb/Hct below normal limits, check CBC
- 3
Evaluate for other anemia causes (bleeding, iron deficiency)
- 4
Document anemia severity and symptoms
- 5
Consider ESA therapy if indicated and document rationale
Ready-to-paste narrative
Patient presents with symptoms consistent with chemotherapy-induced anemia (CIA), a common side effect of cancer treatment. The patient reports fatigue, weakness, and shortness of breath, corroborating the diagnosis of anemia secondary to chemotherapy. On physical examination, the patient exhibited pallor. Laboratory results reveal a decreased hemoglobin and hematocrit, confirming the presence of anemia. The patient's recent chemotherapy regimen, specifically (mention specific chemotherapy agents used), is the likely etiology of the anemia. Differential diagnoses considered included iron deficiency anemia and anemia of chronic disease, but the temporal relationship with chemotherapy supports the diagnosis of chemotherapy-induced anemia. The patient's current treatment plan includes monitoring hemoglobin levels, and potential interventions such as erythropoiesis-stimulating agents (ESAs) or red blood cell transfusion will be considered based on symptom severity and hemoglobin thresholds. Medical coding will utilize ICD-10-CM code D64.81, Anemia due to antineoplastic chemotherapy, and CPT codes for relevant laboratory tests and procedures will be applied. The patient was educated on the importance of medication adherence and follow-up appointments for ongoing monitoring and management of their chemotherapy-induced anemia. Further evaluation and treatment will be adjusted based on the patient's response to therapy and ongoing clinical status.
Common questions and answers
What are the most effective evidence-based management strategies for chemotherapy-induced anemia in adult cancer patients?+
Managing chemotherapy-induced anemia (CIA) effectively requires a multifaceted approach based on the patient's overall health, disease stage, and severity of anemia. Evidence-based strategies include administering erythropoiesis-stimulating agents (ESAs) like epoetin alfa or darbepoetin alfa, particularly when hemoglobin levels fall below 10 g/dL. However, ESAs should be used judiciously, considering potential risks like thrombosis. Iron supplementation is crucial, especially if iron stores are deficient, and intravenous iron may be preferred for faster repletion in patients with functional iron deficiency. Transfusions are reserved for symptomatic anemia or when hemoglobin levels are critically low. Optimizing supportive care, including nutritional counseling and managing comorbidities, is also essential. Consider implementing a patient-blood management program to minimize blood loss and optimize red blood cell production. Explore how integrating these strategies can improve patient outcomes and quality of life.
How do I differentiate chemotherapy-induced anemia from anemia of chronic disease or other anemia types in patients receiving chemotherapy?+
Differentiating chemotherapy-induced anemia (CIA) from other anemia types can be challenging in patients undergoing chemotherapy. While CIA is typically normocytic and normochromic, like anemia of chronic disease, it can sometimes present with microcytic or macrocytic features depending on the chemotherapy regimen and underlying conditions. Key differentiating factors include a temporal relationship between chemotherapy initiation and the onset or worsening of anemia, along with a decrease in reticulocyte count, indicating reduced bone marrow production. Consider evaluating serum iron, ferritin, transferrin saturation, vitamin B12, and folate levels to rule out other contributing factors like iron deficiency, vitamin B12 deficiency, or folate deficiency. A thorough review of the patient's medical history, including pre-chemotherapy blood counts, is crucial. Learn more about the diagnostic workup for CIA to ensure accurate identification and appropriate management.
When should I consider using red blood cell transfusions for chemotherapy-induced anemia, and what are the potential risks and benefits?+
Red blood cell (RBC) transfusions in chemotherapy-induced anemia are typically reserved for patients with symptomatic anemia (e.g., severe fatigue, dyspnea, chest pain) or those with hemoglobin levels below a critical threshold, often around 7-8 g/dL, although this can vary based on individual patient factors. Benefits of RBC transfusions include rapid improvement of oxygen-carrying capacity and symptom relief. However, potential risks exist, including transfusion reactions, iron overload, volume overload, and immunosuppression. Therefore, a careful risk-benefit assessment is essential before each transfusion. Consider implementing strategies to minimize transfusion requirements, such as ESAs, iron supplementation, and patient blood management techniques. Explore the latest guidelines on the appropriate use of RBC transfusions in CIA to ensure optimal patient care.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.